Finerenone APIs, provided by Loncom Pharma, are at the forefront of treating chronic kidney disease and heart failure. These APIs are known for their selectivity in blocking mineralocorticoid receptors, offering a novel approach to managing cardiovascular and renal complications.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
